290 related articles for article (PubMed ID: 22107083)
21. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V
Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
[TBL] [Abstract][Full Text] [Related]
22. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.
Calabresi PA; Giovannoni G; Confavreux C; Galetta SL; Havrdova E; Hutchinson M; Kappos L; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Lublin FD; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
Neurology; 2007 Oct; 69(14):1391-403. PubMed ID: 17761550
[TBL] [Abstract][Full Text] [Related]
23. Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-beta.
Annunziata P; Giorgio A; De Santi L; Zipoli V; Portaccio E; Amato MP; Clerici R; Scarpini E; Moscato G; Iudice A; Vacca G; Orefice G; Morra VB; Maimone D
J Neurol Sci; 2006 May; 244(1-2):97-102. PubMed ID: 16473370
[TBL] [Abstract][Full Text] [Related]
24. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
Barbero P; Verdun E; Bergui M; Pipieri A; Clerico M; Cucci A; Ricci A; Bergamasco B; Durelli L
J Neurol Sci; 2004 Jul; 222(1-2):13-9. PubMed ID: 15240190
[TBL] [Abstract][Full Text] [Related]
25. Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis.
van der Voort LF; Gilli F; Bertolotto A; Knol DL; Uitdehaag BM; Polman CH; Killestein J
Arch Neurol; 2010 Apr; 67(4):402-7. PubMed ID: 20142519
[TBL] [Abstract][Full Text] [Related]
26. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
[TBL] [Abstract][Full Text] [Related]
27. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
[TBL] [Abstract][Full Text] [Related]
28. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L;
N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954
[TBL] [Abstract][Full Text] [Related]
29. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS.
Weinstock-Guttman B; Galetta SL; Giovannoni G; Havrdova E; Hutchinson M; Kappos L; O'Connor PW; Phillips JT; Polman C; Stuart WH; Lynn F; Hotermans C
J Neurol; 2012 May; 259(5):898-905. PubMed ID: 22008873
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study.
De Stefano N; Sormani MP; Stubinski B; Blevins G; Drulovic JS; Issard D; Shotekov P; Gasperini C
J Neurol Sci; 2012 Jan; 312(1-2):97-101. PubMed ID: 21880336
[TBL] [Abstract][Full Text] [Related]
31. Comparing efficacy and side effects of a weekly intramuscular biogeneric/biosimilar interferon beta-1a with Avonex in relapsing remitting multiple sclerosis: a double blind randomized clinical trial.
Nafissi S; Azimi A; Amini-Harandi A; Salami S; shahkarami MA; Heshmat R
Clin Neurol Neurosurg; 2012 Sep; 114(7):986-9. PubMed ID: 22429566
[TBL] [Abstract][Full Text] [Related]
32. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis.
Calabrese M; Bernardi V; Atzori M; Mattisi I; Favaretto A; Rinaldi F; Perini P; Gallo P
Mult Scler; 2012 Apr; 18(4):418-24. PubMed ID: 21228025
[TBL] [Abstract][Full Text] [Related]
33. The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.
Fernández O; Alvarenga MP; Guerrero M; León A; Alonso A; López-Madrona JC; Leyva L; Oliver B; de Ramón E; Luque G; Fernández V
Mult Scler; 2011 Feb; 17(2):192-7. PubMed ID: 21088044
[TBL] [Abstract][Full Text] [Related]
34. New natural history of interferon-beta-treated relapsing multiple sclerosis.
Trojano M; Pellegrini F; Fuiani A; Paolicelli D; Zipoli V; Zimatore GB; Di Monte E; Portaccio E; Lepore V; Livrea P; Amato MP
Ann Neurol; 2007 Apr; 61(4):300-6. PubMed ID: 17444502
[TBL] [Abstract][Full Text] [Related]
35. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.
Zivadinov R; Locatelli L; Cookfair D; Srinivasaraghavan B; Bertolotto A; Ukmar M; Bratina A; Maggiore C; Bosco A; Grop A; Catalan M; Zorzon M
Mult Scler; 2007 May; 13(4):490-501. PubMed ID: 17463072
[TBL] [Abstract][Full Text] [Related]
36. Effect of dose and frequency of interferon beta-1a administration on clinical and magnetic resonance imaging parameters in relapsing-remitting multiple sclerosis.
Cocco E; Marchi P; Floris G; Mascia MG; Deriu M; Sirca A; Mamusa E; Lai M; Mura M; Mallarini G; Marrosu MG
Funct Neurol; 2006; 21(3):145-9. PubMed ID: 17049133
[TBL] [Abstract][Full Text] [Related]
37. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
Chiao E; Meyer K
Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
[TBL] [Abstract][Full Text] [Related]
38. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF
Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960
[TBL] [Abstract][Full Text] [Related]
39. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients.
Kerbrat A; Le Page E; Leray E; Anani T; Coustans M; Desormeaux C; Guiziou C; Kassiotis P; Lallement F; Laplaud D; Diraison P; Rouhart F; Sartori E; Wardi R; Wiertlewski S; Edan G
J Neurol Sci; 2011 Sep; 308(1-2):98-102. PubMed ID: 21665227
[TBL] [Abstract][Full Text] [Related]
40. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial.
Panitch H; Goodin D; Francis G; Chang P; Coyle P; O'Connor P; Li D; Weinshenker B;
J Neurol Sci; 2005 Dec; 239(1):67-74. PubMed ID: 16169561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
